Longitudinal analyses reveal immunological misfiring in severe COVID-19
By C. Lucas, P. Wong, J. Klein, Tiago B. R. Castro, Julio Silva, M. Sundaram, Mallory K. Ellingson, Tianyang Mao, J. E. Oh, Benjamin Israelow and 89 more. Nature, 2020
1,935 citations recorded by the source corpus.
Recent studies have provided insights into the pathogenesis of coronavirus disease 2019 (COVID-19)1–4. However, the longitudinal immunological correlates of disease outcome remain unclear. Here we serially analysed immune responses in 113 patients with moderate or severe COVID-19. Immune profiling revealed an overall increase in innate cell lineages, with a concomitant reduction in T cell number. An early elevation in cytokine levels was associated with worse disease outcomes. Following an early increase in cytokines, patients with moderate COVID-19 displayed a progressive reduction in type 1 (antiviral) and type 3 (antifungal) responses. By contrast, patients with severe COVID-19 maintained these elevated responses throughout the course of the disease. Moreover, severe COVID-19 was accompanied by an increase in multiple type 2 (anti-helminths) effectors, including interleukin-5 (IL-5), IL-13, immunoglobulin E and eosinophils. Unsupervised clustering analysis identified four immune signatures, representing growth factors (A), type-2/3 cytokines (B), mixed type-1/2/3 cytokines (C), and chemokines (D) that correlated with three distinct disease trajectories. The immune profiles of patients who recovered from moderate COVID-19 were enriched in tissue reparative growth factor signature A, whereas the profiles of those with who developed severe disease had elevated levels of all four signatures. Thus, we have identified a maladapted immune response profile associated with severe COVID-19 and poor clinical outcome, as well as early immune signatures that correlate with divergent disease trajectories. A longitudinal analysis of immune responses in patients with moderate or severe COVID-19 identifies a maladapted immune response profile linked to severe disease.
Subfields: Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/cc1cda1c9fb86c460a44f69f3a69153bcba6eafd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Neurology
Citations in the corpus
- Virology, transmission, and pathogenesis of SARS-CoV-2 (2020, background): “34 In the same study many interferons, cytokines, and chemokines were elevated early in disease for patients who had severe disease and higher viral loads.”
- Diverse Functional Autoantibodies in Patients with COVID-19 (2020, methodology): “Moderate disease status (clinical score 1–3) was defined as: SARS-CoV2 infection requiring hospitalization without supplementary oxygen (1); infection requiring non-invasive supplementary oxygen (<3 l/min to maintain SpO2 >92%) (2); and infection requiring non-invasive supplementary oxygen (>3 l/min”
- Complex heatmap visualization (2022, methodology): “ComplexHeatmap has been applied to build comprehensive visualization in a wide range of biology studies, such as on cancers [15], COVID ‐ 19 [16], single cells [17], immunology [18], as well as in other fields, such as oceanology [19] and ecology [20].”
- Distinguishing features of long COVID identified through immune profiling (2022, background): “Infection causes COVID-19, which can manifest as a severe respiratory disease marked by extensive immunological and multiorgan system dysfunction 14–19 .”